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The effect of aqueous and ethanolic extract of Iranian 
propolis on Candida Albicans isolated from the mouth of 
patients with colorectal malignancy undergone 
chemotherapy: An in-vitro study 
 
Abstract 
Background: Candidiasis is one of the most common fungal infections in 
immunosuppressed patients. The condition is usually treated with local and systemic 
antifungal agents. Given the antifungal properties of propolis, it appears this natural resin 
material can be effective in treating this infection. The aim of the present in vitro study 
was to compare the effect of Iranian propolis with those of routine antifungal agents on 
Candida species isolated from the oral candida lesions of patients with cancer, who had 
undergone chemotherapy, and a standard strain of Candida albicans. 
Methods: A total of 23 samples were collected from the oral cavities of patients with 
colorectal cancer, who had undergone chemotherapy with 5-fu. The fungal species were 
determined based on the results of culture in C. albicans chromagar medium, formation of 
the germ tube and formation of vesicles. The MIC of aqueous extract propolis (AEP) and 
ethanolic extract of propolis (EEP) and amphotericin B (AMP-B), fluconazole (FL) and 
nystatin (NYS) were compared. 
Results: A total of 23 oral C. albicans samples were isolated. The MICs of FL and AMP- 
B were similar and less than those of EEP, AEP and NYS (P<0.001). In addition, the MIC 
of AEP was higher than EEP (P<0.001). The MIC of AMP- B on the strains isolated from 
the patients was more than that of the standard strain (P=0.012). 
Conclusion: The aqueous and ethanolic extracts of Iranian propolis exhibited antifungal 
activity, with a greater effect of the EEP compared to the AEP. 
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Candidiasis is the most common oral fungal infections (1). There are many 
predisposing factors, including, chemotherapy, immunosuppressive conditions, mucosal 
injuries and deceased salivary flow (2). In patients with cancer the most common types of 
candidiasis are pseudomembranous and erythematous (3). A systematic review showed 
prevalence of clinical fungal infections during chemotherapy is 38% (4), which is 
attributed to damage of the mucosal barrier and granulocytopenia due to chemotherapy and 
long-term use of broad-spectrum antibiotics and corticosteroids (5,6). On the other hand, 
Sepulveda et al reported30% of oral lesions in patients undergoing chemotherapy had 
clearly been produced by C. albicans (5). To treat oral candidiasis, local antifungal agents, 
such as NYS mouthwashes and clotrimazole and FL lozenges are used; however, these 
agents have various effects (7, 8). Injudicious use of antifungal agents can result in drug 
resistance (9).  
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Systemic medications are used to treat refractory fungal 
infections in immunosuppressed patients (4). However, these 
medications have many side effects and may cause drug 
interactions (10). Propolis or honeybee wax is a resin 
material that is collected by honeybees from different plant 
sources (11). Propolis mainly consists of resin, gum, phenol 
aldehydes (polyphenols), wax and essential fatty acids. 
Phenolic acid, esters and flavonoids are the most important 
constituents of propolis and various biologic properties of 
propolis, including its anti-inflammatory, antifungal, 
antibacterial and antiviral activities, are attributed to these 
constituents. These properties have made propolis as a 
choice for therapeutic purposes (12).  
The antifungal activity of propolis against various 
Candida species has been evaluated in many studies (10, 12). 
The results have shown that the EEP can be an alternative for 
the treatment of candidiasis in HIV patients (13). In addition, 
it has been demonstrated that propolis can be an alternative 
treatment modality for recurrent candidiasis, especially in the 
elderly and in immunosuppressed patients (14).  
There are many reports on increasing Candida species 
resistant to antifungal agents in patients undergoing 
chemotherapy (1). As oral candidiasis is prevalent in patients 
treated with 5-fu (15). The present in vitro study was 
designed to compare the antifungal effects of Iranian 
propolis and other antifungal agents such as NYS, AMP-B 
and FL on Candida species isolated from oral candidiasis in 
patients with 5-fu chemotherapy. 
 
 
Methods  
In the present in vitro study, 23 patients with oral 
candidiasis were evaluated. The samples were collected from 
the oral candida lesions of patients who had referred to 
Shahid Rajaee Hospital in Babolsar for chemotherapy from 
November 2014 to March 2015. All the patients (30-65 years 
old) had colorectal cancer, and a chemotherapy regimen of 
folfox (5-Fu, leucovein eloxatin). Exclusion criteria 
consisted of systemic diseases such as diabetes, active oral 
bacterial infections, vascular collagen diseases, smoking, 
stage 4 cancer, a history of radiotherapy and chemotherapy, 
use of antibiotics and antifungal agents during the previous 
two weeks and a history of corticosteroid use before 
chemotherapy.  
Propolis was prepared in two forms of 25% AEP and 50% 
EEP from Suren Tak Tous Company; NYS (APP Lichem, 
Germany), AMP-B (Sigma, USA) and FL (Sigma, USA) 
were provided from Suren Pharmaceutical Company. The 
standard strain of C. albicans (ATCC) was used to compare. 
Study procedure: This project was approved by the Ethics 
Committee no. 5262 of VP of Research Babol University of 
Medical Sciences. Informed consent was taken from all 
patients. 
Candida's samples were collected from the lesions on the 
tongue, palate and buccal mucosa of the patients with the use 
of a sterile swab impregnated with sterile saline solution. 
Then the samples were cultured on plates containing 
Sabourad’s dextrose agar (Himedi, India) with 
chloramphenicol (Sc) using the linear technique. The 
samples were transferred to the Mycology and Parasitology 
Laboratory of Babol University of Medical Sciences under 
sterile transfer conditions. To identify C. albicans, we used 
the methods of Chromogenic Candida Agar (CCA), vesicle 
formation   and germ tube technique (16, 17, 18). 
All the colonies received from the patients and the 
standard strain of C. albicans were subcultured in Sc medium 
and after growth, a suspension of yeast cells was prepared 
with the use of 2 mL of sterile physiologic serum (normal 
saline) in a shaker. Then McFarland’s 0.5 standard was used 
to reach a concentration of 1×10
6
-5×10
6
 cells per Ml (19). 
Then RPMI 1640 medium was used to reach working 
dilutions of 5×10
2
-2.5×10
3
. 
To determine the minimum inhibitory concentration 
(MIC), the microdilution technique recommended by 
Clinical and Laboratory Standards Institute (CLSI-M27-A3) 
for the RPMI 1640 medium and 96-well sterile microplates 
were used (20). To this step NYS, AMP-B, FL, AEP and 
EEP were prepared in 9 dilutions. NYS, AMP-B and FL 
were prepared at concentrations 0.25-128, 0.310-16 and 
0.125-64µg/ml, respectively; and AEP and EEP were 
prepared at concentrations of 0.4-210 and 0.2-130mg/ml, 
respectively.  
 Dimethyl sulfoxide (DMSO) control solvent was used at 
a maximum concentration of 2 µL in each well (20). The 
negative control wells without any fungal growth (200 mL of 
RPMI) and positive control wells containing fungi without 
any drug or extract were used to control growth. Ethanol, 
too, at a maximum concentration of 12.5%, was used as an 
EEP control and none exhibited any antifungal activity 
against the samples. All the procedures were carried out as 
duplicate. This test was repeated three times to minimize 
errors on the standard strain. All the microplates were 
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incubated at 35°C for 48 hours and finally the microplates 
were inspected visually for turbidity or translucency. 
Turbidity indicated the presence of fungi. Therefore, the last 
translucent well was considered MIC.  
Data were analyzed with SPSS Version 18. Normal 
distribution of variables was confirmed with the use of 
Shappiro-Wilk test. ANOVA and posthoc Tukey tests were 
used to compare data collected after application of different 
treatment modalities. Non-paired t-test was used to compare 
MIC of each fungal strain in each group with the standard 
strain. Statistical significance was set at P<0.05.  
 
 
Results 
In the present study, Candida samples were cultured from 
23 patients with colorectal cancer, who had clinical oral 
candidiasis. C. albicans was isolated from 22 samples and 
the other one was C. glabrata. The Candida species were 
differentiated based on the formation of germ tube, 
formation of vesicles and the results of culturing in the C. 
albicans chromagar culture medium.  
The results mainly achieved based on dilution of the 
liquid culture medium, showed that AMP-B, NYS, FL and 
AEP and EEP had inhibitory effects on C. albicans. The 
MICs for AMP-B, FL, NYS, EEP, and AEP were 0.35 
µg/mL, 1.54 µg/mL, 11.83 µg/mL 2.74 mg/mL and 9.01 
mg/mL, respectively. As shown in figures 1 and 2, the lower 
and higher concentrations belonged to AMP-B and AEP, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MICs of antifungal agents in samples collected 
from the patients and standard strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. MICs of AEP and EEP in samples collected 
from the patients and standard strain.  
 
The results showed that the fungal inhibitory effect of 
AMP-B was similar to that of FL and its effect was higher 
than that of the NYS, EEP and AEP (P<0.001). In addition, 
the antifungal activity of EEP was higher than AEP 
(P<0.001). 
Overall, both the EEP and AEP had inhibitory effects on 
fungi, with higher effect of EEP compared to the AEP 
(P<0.001). There were no significant difference in the MICs 
of FL, NYS and EEP and AEP between standard C. albicans 
and the candidiasis isolated from the patients, but higher 
doses of AMP-B were required to inhibit samples isolated 
from the patients’ oral cavities compared to the standard 
strain (p=0.012). 
 
 
Discussion 
In the present study, the antifungal effects of the AEP and 
EEP were compared with those of routine antifungal 
medications AMP-B, FL and NYS. Totally, the minimum 
inhibitory concentrations (MICs) of AMP-B and FL were 
similar to each other but less than those of NYS, EEP and 
AEP, moreover, the MIC of EEP was lower than that of 
AEP. The compositions of different propolis products are 
different depending on plant species, local climate and 
environment, resulting in differences in the biologic 
properties of propolis in different geographic locations; 
however, the antifungal activity of this material has been 
show (21) and since propolis is a natural agent, its antifungal 
effects can be used with higher dose for patients. The 
antifungal properties of propolis are mainly attributed to its 
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flavonoid (polyphenol) and cinnamic acid contents (22). It 
has been shown that propolis inhibits DNA replication in 
fungi, and indirectly inhibits cellular division (10). On the 
other hand, Wander et al. in 2008 showed that propolis can 
reduce the Candida adhesion on denture surface more than 
fluconazole and nystatin (23). 
 Thus, it might be used as an ideal combination for the 
treatment of fungal infections (24). A synergistic effect was 
observed for the action of EEP in combination with 
fluconazole and voriconazole against C. albicans by 
Katarzyna in 2018 (25). Christian evaluated MICs of six 
different commercial extracts of propolis and showed that 
despite differences in polyphenol concentrations, all of them 
were able to prevent the growth of C. albicans (22). Martin 
indicated EEP had effect on C. albicans isolated from 
patients with AIDS (13). An in vitro study in 2016 has 
shown that propolis has significant antifungal activity, which 
is comparable with fluconazole and itraconazole against 
yeasts isolated from blood culture in adult patients in ICUs 
(26). In the present study, the antifungal effect of propolis on 
samples isolated from immunosuppressed individuals was 
also evaluated. It was shown that both the EEP and AEP 
have antifungal activity on the standard strain, and C. 
albicans strains isolated from the mucosa of individuals who 
were immunosuppressed. Since in previous studies the AEP 
has been used less frequently, in this study two different 
extracts were used and compared. The EEP exhibited greater 
antifungal activity compared to the AEP, which might be 
attributed to different ability of solvents (water or alcohol) to 
extract flavonoid components from propolis. Ethyl alcohol 
can provide more flavonoids than water (27).  
In a study in 2006 by Mello, the MIC of 20% EEP against 
C. albicans was similar to that of NYS (18). However, in the 
present study, EEP exhibited lower antifungal activity 
compared to NYS. It appears such difference is due to 
differences in geographical locations, plant species and 
climates in the origins of propolis in this study. The higher 
percentage of alcohol in this propolis extract. Since the bulk 
of propolis consists of resin and wax, a higher concentration 
of alcohol can result in greater release of these soluble 
substances (12). 
In the present study, the MIC of AMP-B on C. albicans 
strains isolated from the oral candida lesions was higher than 
the standard strain of C. albicans, which means higher 
concentration of AMP-B was needed to inhibit C. albicans 
strain isolated form patients. According to the MIC of AMP-
B and EEP on standard and isolated strains of C. albicans, 
higher doses of AMP-B are needed to inhibit C. albicans 
strains isolated from immunosuppressed patients than 
standard strain of which this increase in dose is not needed 
for EEP. 
In conclusion the aqueous and ethanolic extracts of 
Iranian propolis exhibited antifungal activity but the 
ethanolic extract was more effective than the aqueous 
extract. In addition, the EEP, compared to AMP-B exhibited 
antifungal activity against both C. albicans species isolated 
from the patients and the standard C. albicans species.  
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